Medicenna to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

TORONTO and HOUSTON, TX, Sept. 6, 2017 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, Chairman, President and Chief Executive Officer will be presenting at the Rodman & Renshaw 19th Annual Global Investment Conference sponsored by H.C. Wainwright & Co., LLC.  in New York City on Tuesday, September 12th, at 4:15 PM Eastern Standard Time at the Lotte New York Palace Hotel. Medicenna is currently enrolling patients in a Phase 2b trial of MDNA55 for recurrent glioblastoma (rGB), the most common and uniformly fatal form of brain cancer.

Dr. Merchant will provide a corporate overview of the Company's recent activities and strategic direction and will be available along with Elizabeth Williams, Medicenna's Chief Financial Officer, for one-on-one meetings from September 10 – 12, 2017.

Presentation details:

Time:					4:15 p.m. ET
Date:					Tuesday, September 12, 2017
Location:					Lotte New York Palace Hotel, New York, NY

A live webcast of the Medicenna presentation will be accessible by visiting:

http://wsw.com/webcast/rrshq27/mdna/

The webcast will be archived shortly after the live event and will be available for 90 days through the Medicenna website at www.medicenna.com

About Medicenna Therapeutics Corp.

Medicenna is a clinical stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™ (ECs).  Its wholly owned subsidiary, Houston-based Medicenna BioPharma, is specifically targeting the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Medicenna's lead IL4-EC, MDNA55 is enrolling patients in a Phase 2b clinical trial for rGB at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGB, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment, offering a unique treatment paradigm for a large majority of cancer patients.

For more information, please visit www.medicenna.com.

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding future plans and objectives of the Company and others are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the annual information form of the Company dated June 15, 2017 and in other filings made by the Company with the applicable securities regulators from time to time.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by Canadian securities law.

SOURCE Medicenna Therapeutics Corp.

Copyright 2017 PR Newswire